Medical Center Excelsior OOD — Clinical Trial Site

55 Registered trials

12 Currently recruiting

Organisation

Medical Center Excelsior OOD

Location

Sofiya, Bulgaria

Identifier

ORG-100042968

Address

Lozenets, Ulitsa Golo Birdo 4, 1407, Bulgaria

Departments

#206
#40811
#7207
0404: Allergology
0903; NA
10028
1504; NA
3503
4119
7303: NA
7326: NA
9052
BG017
BG018
BG10010
BGR05443
Clinic of Allergology and Immunology
Clinic of Rheumatology
Clinical Allergology medical office
Internal Diseases, Clinical Allergology
Medical Center
Medical Center Excelsior OOD
N.A
N/A
NA
Not applicable
Rheumatology office

Clinical trials at this site (55)

Search interface

A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma Ended

2023-508039-29-00 Moderate-to-severe Asthma 4 2024-09-16
A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended

2023-505435-12-00 Asthma 5 2024-06-04
A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended

2023-508085-15-00 Chronic Obstructive Pulmonary Disease 5 2024-05-15
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV… Ended

2023-507456-69-00 Atopic Dermatitis 4 2024-04-25
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic … Ended

2023-503655-10-00 Systemic Lupus Erythematosus (SLE). 5 2023-11-20
Phase 2 Placebo-controlled Study to Assess the Safety, Efficacy, and PK of ESK-001 in SLE Ended

2022-502105-15-00 Systemic lupus erythematosus 4 2023-10-20
A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad … Ended

2022-503004-24-00 Influenza virus 5 2023-10-20
An extension study of long-term efficacy, safety and tolerability of remibrutinib in chronic spontaneous urticaria patients who completed pr… Ended

2024-510818-33-00 Chronic Spontaneous Urticaria 5 2023-01-24
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients with Uncontrolled Moderate to Sev… Ended

2024-513423-16-00 Asthma 6 2022-08-25
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus Ended

2024-513031-24-00 Moderate-to-severe Systemic Lupus Erythematosus (SLE) 10 2021-10-22
A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended

2023-504734-21-00 Psoriatic arthritis (PsA) 5 2021-08-30
Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended

2024-514404-13-00 Atopic Dermatitis 5 2020-10-01
A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or … Ended

2023-505478-14-00 Psoriatic Arthritis 5 2019-05-09
Open-label basket study for safety and pharmacokinetics evaluation of INF904 in subjects with CSU or HS Ended

2024-515615-22-00 Moderate to Severe Chronic Spontaneous Urticaria (CSU) 4 2025-04-02
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome Ended

2023-507680-19-00 Sjögren’s Syndrome 4 2024-11-28
A Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Influenza Vaccine Compared with a Licensed Influenza … Ended

2024-516240-26-00 Influenza 5 2024-10-11
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants with Severe Asthma (VALIANT) Ended

2023-507410-27-00 Severe Asthma 4 2024-06-19
A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi… Ended

2022-501421-20-00 Gout with hyperuricemia 5 2024-04-09
A study evaluating the effects of GLPG3667 given as oral treatment in adults with active systemic lupus erythematosus. Ended

2023-503183-16-00 Systemic Lupus Erythematosus 4 2024-01-16
A Phase 2 study to evaluate the efficacy and safety of RPT193 in adults with moderate-to-severe T2-high asthma who are partially controlled … Ended

2022-502854-16-00 Asthma 4 2023-11-26
Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy Ended

2022-502208-64-00 Asthma 4 2023-11-25
BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous Urticaria Ended

2024-514764-72-00 Chronic Urticaria 5 2023-09-27
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Atopic Dermatitis 5 2023-05-11